Tagged with LEO Pharma

Denmark Once a quiet legacy player in dermatology, LEO Pharma is re-emerging with renewed focus and ambition under CEO Christophe Bourdon. With global leadership experience at Amgen and Alexion, Bourdon is guiding the century-old company through a bold transformation, restoring profitability, embracing external innovation, and laying the groundwork for a potential…

Denmark LEO Pharma has been in the midst of a shakeup since the beginning of 2022. After naming a new CEO and announcing a major restructuring, the Danish dermatology pharma has let a considerable number of employees go, closed research centres and restructured its R&D team. While LEO’s financials look promising…

Greece After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that the May 2023 election victory of incumbent Greek Prime Minister Kyriakos Mitsotakis (and the heavy defeat handed to his left…

Greece Nicos Ragoussis explains how he steered the Greek affiliate of Danish dermatology specialist LEO Pharma through the unprecedented challenges of the government-debt crisis era, the ongoing market access hurdles that still remain, and why he is highly optimistic about future business prospects.   The hard times are behind us and…

Greece The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving away from its past austerity policies is particularly significant for Greece. Severely hit by the financial crisis a decade ago and thrown off its course to recovery by…

Denmark Catherine Mazzacco’s two-year stint as CEO of Danish dermatology specialist LEO Pharma is over. With the company’s board planning for an initial public offering (IPO) within the next four-to-five years, LEO is now on the lookout for a replacement with capital market experience and the ability to steer the firm…

Denmark Denmark’s four largest pharma companies – Novo Nordisk, Lundbeck, LEO Pharma, and ALK – are all at least partly owned by independent foundations, which means that their profits are divided between their shareholders and the foundations themselves, with funds then channelled into academia and biotech start-ups. Here, a variety of…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

USA With COVID-19 having wreaked havoc on global operations, the pharma industry is understandably focused on leveraging its collective resources and knowhow in discovering and delivering prophylactics and therapeutics against the novel coronavirus. However, even as great strides have been made on that front, companies have to continue delivering their existing…

USA Christopher Posner, US head for Danish medical dermatology specialist LEO Pharma, outlines how a mid-sized European company navigates the US market’s complex access and affordability issues, the innovations that the company is bringing to the US, and his leadership and HR philosophy.   My priority leading LEO Pharma Inc. in…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Sweden The Nordic headquarters of Danish medical dermatology specialist LEO Pharma sits in Sweden, led by the recently appointed Klaus Abel. Abel discusses the importance of Sweden to the global group, its ambitious goal of helping 125 million patients by 2025, and the leading role that the Nordics has to play…